A Phase 1/2 interventional study of Givinostat in Polycythemia Vera, sponsored by Italfarmaco. Completed at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-30.
Sponsored by Italfarmaco · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Polycythemia Vera with a site in Italy — 8 open to participants now, 15 under way, 3 of them phase 3. Polycythemia Vera · Italy.
Among the 44 studies in Polycythemia Vera with a site in Italy, this one is the 26th largest by enrollment of the 31 interventional ones that give a count, is one of 6 that started in 2013, is one of 3 in phase 1/2, and was the 20th registered.
278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
Browse Polycythemia Vera studies →8 of the 44 studies in Polycythemia Vera with a site in Italy are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in Italy, United States, Australia and 8 more countries
Ages 18+
Prelude Therapeutics Incorporated · Sites in Italy, United States, Australia and 2 more countries
Ages 18+
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · Sites in Italy, United States, Germany and 2 more countries
Ages 18–100
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Sites in Italy
Ages 16+
Merck Sharp & Dohme LLC · Sites in Italy, United States, Australia and 3 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 11 · Phase 4 1
First in 1999; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is close to the median of 52 across 204 interventional studies indexed under Polycythemia Vera.
Median enrollment 127 across the 31 interventional studies, 429 across the 13 observational. Of the 29 that completed or were terminated, 13 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 44 have an industry lead sponsor. The 10 most frequent:
Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Italfarmaco has 5 studies filed under Polycythemia Vera — fewer than ten, so there is no comparison to draw.
5 of the studies in Polycythemia Vera with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01761968ItalfarmacoLong-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | 2026-12 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT07203768FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSA ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes | 2026-12-31 |
| NCT05548062Novartis PharmaceuticalsStudy to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | 2027-08-31 |
| NCT07518940Carmen FavaENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies in Polycythemia Vera with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a two-part, multicenter, open label, non-randomized, phase Ib/II study to assess the safety and tolerability, Maximum Tolerated Dose and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera. Part A is the dose finding part while Part B is assessing the preliminary efficacy. Patients will be enrolled either in Part A or Part B and transition from one part to the other is not allowed.
Eligible patients for this study will have a confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization criteria. Only if the enrolment in Part A is slow (i.e. \< 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with chronic myeloproliferative neoplasms.
Study therapy will be administered in 28 day cycles (4 weeks of treatment). Disease response will be evaluated according to the European LeukemiaNet criteria after 3 and 6 cycles (i.e. at weeks 12 and 24, respectively) of treatment with Givinostat for both parts of the study. All phlebotomies performed in the first 3 weeks of treatment will not be counted to assess the clinico-haematological response.
The study will last up to a maximum of 24 weeks of treatment. However, after completion of the trial, all patients achieving clinical benefit will be allowed to continue treatment with Givinostat (at the same dose and schedule) in a long-term study.
Safety will be monitored at each visit throughout the entire duration of the study. Treatment will be administered on an outpatient basis and patients will be followed regularly with physical and laboratory tests, as specified in the protocol; in case of hospitalization, the treatment will be continued or interrupted according to the Investigators' decision.
This is a two-part, multicenter, open label, non-randomized, phase Ib/II study to assess the safety and tolerability, MTD and preliminary efficacy of Givinostat in patients with JAK2V617F positive PV.
Part A is the dose escalation portion of the study and, once the MTD has been established, Part B will commence where the preliminary efficacy of Givinostat in PV patients will be established. Patients will be enrolled either in Part A or Part B and transition from one part to the other is not allowed. Only PV patients from Part A assigned to the dose selected for Part B (MTD) may be counted towards the efficacy assessment in Part B.
Eligible patients for this study will have a confirmed diagnosis of PV according to the revised WHO criteria and the JAK2V617F positivity. Only if the enrolment in Part A is slow (i.e. \< 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with cMPN.
After providing informed written consent before undertaking any protocol-related procedure, a unique patient identification code (i.e. patient screening ID which will be a combination of his/her site ID, study part ID and patient screening number, e.g. IT01-A01) will be assigned to each patient and it will identify the patient within his/her enrolment confirmation by Italfarmaco S.p.A. or its designee and never be reused in case of screening failure. After the enrolment confirmation and the assignation of the dose level before the first drug intake, a unique patient identification code (i.e. patient ID which will be a combination of patient screening number ID and dose level ID, e.g. IT01-A01-DL1) will be assigned to each patient and it will identify the patient throughout his/her participation in the study and never be reused in case of premature drop-out.
Study therapy will be administered in 28 day cycles. In fact, the "cycle" is defined as 4 weeks of treatment.
Disease response will be evaluated according to the clinico-haematological ELN criteria after 3 and 6 cycles (i.e. at weeks 12 and 24, respectively) of treatment with Givinostat for both parts of the study. All phlebotomies performed in the first 3 weeks of treatment will not be counted to assess the clinico-haematological response.
The study will last up to a maximum of 24 weeks of treatment. However, after completion of the trial, all patients achieving clinical benefit will be allowed to continue treatment with Givinostat (at the same dose and schedule) in a long-term study (Study N.: DSC/11/2357/44).
Safety will be monitored at each visit throughout the entire duration of the study. Treatment will be administered on an outpatient basis and patients will be followed regularly with physical and laboratory tests, as specified in the protocol; in case of hospitalization, the treatment will be continued or interrupted according to the Investigators' decision.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have an active/not controlled disease defined as
Note that if the enrolment in Part A is slow (i.e. \< 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with chronic myeloproliferative neoplasms. In this case, the inclusion criteria 5 will be modified as following only for Part A:
Exclusion Criteria:
Clinically significant cardiovascular disease including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part A patients will treated in dose levels at the following daily doses of Givinostat: * 50 mg b.i.d., * 100 mg b.i.d.; * 150 mg b.i.d., * 200 mg b.i.d.; * 150 mg t.i.d.; * 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose. In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.
Drug: Givinostat
In Part A patients will treated in dose levels at the following daily doses of Givinostat: * 50 mg b.i.d., * 100 mg b.i.d.; * 150 mg b.i.d., * 200 mg b.i.d.; * 150 mg t.i.d.; * 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose. In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.
Also known as: Givinostat (ITF2357)
Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study
Evaluations were performed on the type, incidence and severity of TEAEs, graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03, following administration of givinostat for up to 6 cycles of treatment in Part A. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / treatment-emergent serious adverse event (TESAE) corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment.
Time frame: 168 days (up to Cycle 6 Day 28 in Part A).
Number of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the Study
The MTD of givinostat was based only on Cycle 1 DLTs. A DLT was defined as the following drug-related toxicity: * Grade 4 hematological toxicity, or * Grade 3 febrile neutropenia, or * Grade ≥3 non-hematological toxicity (with the exception Grade 3 diarrhea without adequate supportive care lasting less than 3 days, and Grade 3 nausea or vomiting without adequate supportive care lasting less than 3 days), or * Any drug-related serious AE, or * Any toxicity clearly not related to disease progression or intercurrent illness requiring interruption of dosing for more than 3 days during first cycle. At end of Cycle 1, for the third patient in each DL, the safety of the 3 patients treated for 1 cycle was reviewed and it was decided if the dose should be escalated or not. Results are reported as the number of patients with DLT events for Cycle 1 in Part A.
Time frame: 28 days (up to Cycle 1 Day 28 in Part A).
Number of Patients Experiencing TEAEs After 3 Cycles in Part B of the Study
Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 3 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment.
Time frame: 84 days (up to Cycle 3 Day 28 in Part B).
Overall Response Rate (ORR) (i.e. Complete Response [CR] and Partial Response [PR]) After 3 Cycles in Part B of the Study
ORR, CR and PR following administration of givinostat at MTD for 3 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological European LeukemiaNet (ELN) response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. CR defined as: 1. Hematocrit (HCT) \<45% without phlebotomy, and 2. Platelets ≤400 x10\^9/litre (L), and 3. White Blood Cell count ≤10 x10\^9/L, and 4. Normal spleen size, and 5. No disease-related systemic symptoms (i.e. pruritus, headache, microvascular disturbances). PR defined as: Patients not fulfilling CR and 1. HCT \<45% without phlebotomy, or 2. Response in ≥3 other criteria.
Time frame: 84 days (up to cycle 3 Day 28 in Part B).
ORR After 3 Cycles and After 6 Cycles in Part A of the Study
ORR following administration of givinostat after 3 cycles and after 6 cycles in Part A, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. Analysis performed using the dataset for all Part A patients combined.
Time frame: 84 and 168 days (up to Cycle 3 Day 28 and Cycle 6 Day 28 in Part A).
ORR After 6 Cycles in Part B of the Study
ORR following administration of givinostat at the MTD for 6 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis.
Time frame: 168 days (up to Cycle 6 Day 28 in Part B).
Number of Patients Experiencing TEAEs After 6 Cycles in Part B of the Study
Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 6 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment. Results are reported as number of patients with TEAEs for each of the indicated categories.
Time frame: 168 days (up to Cycle 6 Day 28 in Part B).
Assessment of Maximum Plasma Concentration (Cmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study
Pharmacokinetic (PK) evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.
Time frame: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Assessment of Time to Maximum Plasma Concentration (Tmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.
Time frame: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Assessment of Time of the Last Detectable Concentration (Tlast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.
Time frame: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Assessment of Area Under Plasma Concentration Versus the Time Curve up to the Last Detectable Concentration (AUClast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.
Time frame: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Assessment of Area Under Plasma Concentration Versus the Time Curve in the Dosing Interval (0-12 Hours) (AUC0-12) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUC0-12 was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note:concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) across all dose groups and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.
Time frame: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Assessment of Cmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.
Time frame: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Assessment of Tmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.
Time frame: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Assessment of Tlast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.
Time frame: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Assessment of AUClast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.
Time frame: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Assessment of AUC0-12 of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2374 (Cycle 1 Day 28) across all dose groups and for ITF2375 in the 50 mg b.i.d. dose group was not available for PK analysis.
Time frame: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
This was a 2-part, multisite, open-label, non-randomized study to assess givinostat in patients with JAK2\^V617F positive Polycythemia Vera. Part A assessed safety and was the dose escalation portion of study, while Part B assessed preliminary efficacy. Patients were enrolled in 5 countries (France, Germany, Italy, Poland and the United Kingdom).
| Milestone | Givinostat DL0 (50 mg b.i.d.) (Part A) | Givinostat DL1 (100 mg b.i.d.) (Part A) | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Givinostat DL6 (100 mg + 50 mg) (Part A) | Givinostat at MTD (100 mg b.i.d.) (Part B) |
|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 36 |
| Received study drug | 3 | 3 | 3 | 3 | 35 |
| Completed | 3 | 2 | 1 | 3 | 27 |
| Not completed | 0 | 1 | 2 | 0 | 9 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 5 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Patient decision to stop study drug | 0 | 0 | 0 | 0 | 1 |
Evaluations were performed on the type, incidence and severity of TEAEs, graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03, following administration of givinostat for up to 6 cycles of treatment in Part A. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / treatment-emergent serious adverse event (TESAE) corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment.
| Participants | Givinostat DL0 (50 mg b.i.d.) (Part A) | Givinostat DL1 (100 mg b.i.d.) (Part A) | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Givinostat DL6 (100 mg + 50 mg) (Part A) |
|---|---|---|---|---|
| TEAE | 3 | 3 | 3 | 3 |
| Drug-related TEAE | 1 | 3 | 3 | 1 |
| TESAE | 0 | 1 | 0 | 1 |
| Drug-related TESAE | 0 | 0 | 0 | 0 |
| Death due to any cause | 0 | 0 | 0 | 0 |
| Grade 3 TEAE | 0 | 2 | 1 | 1 |
| Grade 3 drug-related TEAE | 0 | 2 | 1 | 0 |
| Grade 4 TEAE | 0 | 0 | 1 | 0 |
| Grade 4 drug-related TEAE | 0 | 0 | 1 | 0 |
| Grade 5 TEAE | 0 | 0 | 0 | 0 |
| Discontinuation due to TEAE | 0 | 1 | 1 | 0 |
| Discontinuation due to drug-related TEAE | 0 | 1 | 1 | 0 |
| Discontinuation due to TESAE | 0 | 0 | 0 | 0 |
| Discontinuation due to drug-related TESAE | 0 | 0 | 0 | 0 |
The MTD of givinostat was based only on Cycle 1 DLTs. A DLT was defined as the following drug-related toxicity: * Grade 4 hematological toxicity, or * Grade 3 febrile neutropenia, or * Grade ≥3 non-hematological toxicity (with the exception Grade 3 diarrhea without adequate supportive care lasting less than 3 days, and Grade 3 nausea or vomiting without adequate supportive care lasting less than 3 days), or * Any drug-related serious AE, or * Any toxicity clearly not related to disease progression or intercurrent illness requiring interruption of dosing for more than 3 days during first cycle. At end of Cycle 1, for the third patient in each DL, the safety of the 3 patients treated for 1 cycle was reviewed and it was decided if the dose should be escalated or not. Results are reported as the number of patients with DLT events for Cycle 1 in Part A.
| participants | Givinostat DL0 (50 mg b.i.d.) (Part A) | Givinostat DL1 (100 mg b.i.d.) (Part A) | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Givinostat DL6 (100 mg + 50 mg) (Part A) |
|---|---|---|---|---|
| Number of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the Study | 0 | 1 | 0 | 0 |
Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 3 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment.
| Participants | Givinostat at MTD (100 mg b.i.d.) (Part B) |
|---|---|
| TEAE | 35 |
| Drug-related TEAE | 33 |
| TESAE | 2 |
| Drug-related TESAE | 1 |
| Death due to any cause | 0 |
| Grade 3 TEAE | 10 |
| Grade 3 drug-related TEAE | 7 |
| Grade 4 TEAE | 0 |
| Grade 4 drug-related TEAE | 0 |
| Grade 5 TEAE | 0 |
| Discontinuation due to TEAE | 2 |
| Discontinuation due to drug-related TEAE | 2 |
| Discontinuation due to TESAE | 0 |
| Discontinuation due to drug-related TESAE | 0 |
ORR, CR and PR following administration of givinostat at MTD for 3 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological European LeukemiaNet (ELN) response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. CR defined as: 1. Hematocrit (HCT) \<45% without phlebotomy, and 2. Platelets ≤400 x10\^9/litre (L), and 3. White Blood Cell count ≤10 x10\^9/L, and 4. Normal spleen size, and 5. No disease-related systemic symptoms (i.e. pruritus, headache, microvascular disturbances). PR defined as: Patients not fulfilling CR and 1. HCT \<45% without phlebotomy, or 2. Response in ≥3 other criteria.
| percentage of participants | Givinostat at MTD (100 mg b.i.d.) (Part B) |
|---|---|
| ORR (CR + PR) | 80.6 (62.53 to 92.55) |
| CR | 9.7 (2.04 to 25.75) |
| PR | 71.0 (51.96 to 85.78) |
ORR following administration of givinostat after 3 cycles and after 6 cycles in Part A, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. Analysis performed using the dataset for all Part A patients combined.
| percentage of participants | Givinostat Total (Part A) |
|---|---|
| Cycle 3 Day 28 | 72.7 (39.03 to 93.98) |
| Cycle 6 Day 28 | 72.7 (39.03 to 93.98) |
ORR following administration of givinostat at the MTD for 6 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis.
| percentage of participants | Givinostat at MTD (100 mg b.i.d.) (Part B) |
|---|---|
| ORR After 6 Cycles in Part B of the Study | 80.6 (62.53 to 92.55) |
Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 6 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment. Results are reported as number of patients with TEAEs for each of the indicated categories.
| participants | Givinostat at MTD (100 mg b.i.d.) (Part B) |
|---|---|
| TEAE | 35 |
| Drug-related TEAE | 33 |
| TESAE | 2 |
| Drug-related TESAE | 1 |
| Death due to any cause | 0 |
| Grade 3 TEAE | 12 |
| Grade 3 drug-related TEAE | 10 |
| Grade 4 TEAE | 0 |
| Grade 4 drug-related TEAE | 0 |
| Grade 5 TEAE | 0 |
| Discontinuation due to TEAE | 2 |
| Discontinuation due to drug-related TEAE | 2 |
| Discontinuation due to TESAE | 0 |
| Discontinuation due to drug-related TESAE | 0 |
Pharmacokinetic (PK) evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.
| nanograms per millilitre (ng/mL) | Givinostat DL0 (50 mg b.i.d.) (Part A PK Analysis Set) | Givinostat DL1 (100 mg b.i.d.) (Part A PK Analysis Set) | Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set) |
|---|---|---|---|
| Givinostat Cycle 1 Day 1 | 60.2 ± 43.1 | 54.3 ± 17.2 | 82.5 ± 24.4 |
| ITF2374 Cycle 1 Day 1 | — | 3.74 ± 4.09 | 5.69 ± 2.87 |
| ITF2375 Cycle 1 Day 1 | — | 68.6 ± 21.2 | 101 ± 24.5 |
| Givinostat Cycle 1 Day 28 | 22.4 ± 8.92 | 73.3 ± 31.9 | 290 ± 330 |
| ITF2374 Cycle 1 Day 28 | — | 19.7 ± 7.24 | 31.3 ± 4.95 |
| ITF2375 Cycle 1 Day 28 | 110 ± 22.8 | 259 ± 75.9 | 376 ± 215 |
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.
| hours | Givinostat DL0 (50 mg b.i.d.) (Part A PK Analysis Set) | Givinostat DL1 (100 mg b.i.d.) (Part A PK Analysis Set) | Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set) |
|---|---|---|---|
| Givinostat Cycle 1 Day 1 | 2.00 (1.92 to 3.00) | 2.00 (2.00 to 2.00) | 3.00 (2.00 to 3.00) |
| ITF2374 Cycle 1 Day 1 | — | 8.00 (8.00 to 8.00) | 8.00 (3.00 to 8.00) |
| ITF2375 Cycle 1 Day 1 | — | 3.00 (2.00 to 3.00) | 2.50 (2.00 to 3.00) |
| Givinostat Cycle 1 Day 28 | 3.90 (3.83 to 4.00) | 1.50 (1.00 to 3.98) | 2.05 (1.05 to 4.00) |
| ITF2374 Cycle 1 Day 28 | — | 8.00 (0.00 to 8.00) | 2.00 (1.05 to 4.05) |
| ITF2375 Cycle 1 Day 28 | 2.00 (2.00 to 2.00) | 1.99 (1.00 to 3.98) | 4.00 (0.00 to 4.05) |
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.
| hours | Givinostat DL0 (50 mg b.i.d.) (Part A PK Analysis Set) | Givinostat DL1 (100 mg b.i.d.) (Part A PK Analysis Set) | Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set) |
|---|---|---|---|
| Givinostat Cycle 1 Day 1 | 7.97 ± 0.0462 | 8.00 ± 0.00 | 8.00 ± 0.00 |
| ITF2374 Cycle 1 Day 1 | — | 8.00 ± 0.00 | 8.00 ± 0.00 |
| ITF2375 Cycle 1 Day 1 | — | 8.00 ± 0.00 | 8.00 ± 0.00 |
| Givinostat Cycle 1 Day 28 | 8.05 ± 0.249 | 7.00 ± 2.01 | 8.02 ± 0.0252 |
| ITF2374 Cycle 1 Day 28 | — | 7.00 ± 2.01 | 8.02 ± 0.0252 |
| ITF2375 Cycle 1 Day 28 | 3.00 ± 1.41 | 7.00 ± 2.01 | 6.70 ± 2.30 |
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.
| ng*h/mL | Givinostat DL0 (50 mg b.i.d.) (Part A PK Analysis Set) | Givinostat DL1 (100 mg b.i.d.) (Part A PK Analysis Set) | Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set) |
|---|---|---|---|
| Givinostat Cycle 1 Day 1 | 208 ± 136 | 238 ± 55.6 | 429 ± 109 |
| ITF2374 Cycle 1 Day 1 | — | 14.4 ± 19.0 | 29.6 ± 9.64 |
| ITF2375 Cycle 1 Day 1 | — | 416 ± 153 | 611 ± 146 |
| Givinostat Cycle 1 Day 28 | 132 ± 45.1 | 359 ± 203 | 1100 ± 1050 |
| ITF2374 Cycle 1 Day 28 | — | 102 ± 11.7 | 158 ± 42.6 |
| ITF2375 Cycle 1 Day 28 | 263 ± 192 | 1390 ± 675 | 1780 ± 1190 |
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUC0-12 was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note:concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) across all dose groups and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.
| ng*h/mL | Givinostat DL0 (50 mg b.i.d.) (Part A PK Analysis Set) | Givinostat DL1 (100 mg b.i.d.) (Part A PK Analysis Set) | Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set) |
|---|---|---|---|
| Givinostat Cycle 1 Day 1 | 235 ± 146 | 289 ± 68.9 | 508 ± 107 |
| ITF2375 Cycle 1 Day 1 | — | 598 ± 259 | 870 ± 182 |
| Givinostat Cycle 1 Day 28 | 161 ± 51.8 | 533 ± 223 | 1180 ± 1050 |
| ITF2375 Cycle 1 Day 28 | 863 ± NA | 2020 ± 1000 | 2340 ± 970 |
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.
| ng/mL | Givinostat 100 mg b.i.d. (Part B PK Analysis Set) | Givinostat 75 mg b.i.d. (Part B PK Analysis Set) | Givinostat 50 mg b.i.d. (Part B PK Analysis Set) |
|---|---|---|---|
| Givinostat Cycle 1 Day 1 | 71.5 ± 34.4 | — | — |
| ITF2374 Cycle 1 Day 1 | 7.85 ± 4.89 | — | — |
| ITF2375 Cycle 1 Day 1 | 161 ± 72.9 | — | — |
| Givinostat Cycle 2 Day 28 | 90.8 ± 33.5 | 64.0 ± 22.6 | 62.6 ± 21.8 |
| ITF2374 Cycle 2 Day 28 | 32.3 ± 21.0 | 22.6 ± 11.2 | 21.4 ± 0.424 |
| ITF2375 Cycle 2 Day 28 | 320 ± 238 | 203 ± 78.7 | — |
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.
| hours | Givinostat 100 mg b.i.d. (Part B PK Analysis Set) | Givinostat 75 mg b.i.d. (Part B PK Analysis Set) | Givinostat 50 mg b.i.d. (Part B PK Analysis Set) |
|---|---|---|---|
| Givinostat Cycle 1 Day 1 | 2.00 (0.00 to 8.00) | — | — |
| ITF2374 Cycle 1 Day 1 | 8.00 (2.08 to 8.17) | — | — |
| ITF2375 Cycle 1 Day 1 | 3.00 (1.83 to 8.00) | — | — |
| Givinostat Cycle 2 Day 28 | 2.00 (0.00 to 4.07) | 2.00 (1.00 to 8.00) | 0.985 (0.00 to 1.97) |
| ITF2374 Cycle 2 Day 28 | 4.00 (0.00 to 8.00) | 3.04 (1.00 to 8.00) | 5.99 (3.97 to 8.00) |
| ITF2375 Cycle 2 Day 28 | 2.00 (0.00 to 4.00) | 2.00 (1.00 to 8.00) | — |
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.
| hours | Givinostat 100 mg b.i.d. (Part B PK Analysis Set) | Givinostat 75 mg b.i.d. (Part B PK Analysis Set) | Givinostat 50 mg b.i.d. (Part B PK Analysis Set) |
|---|---|---|---|
| Givinostat Cycle 1 Day 1 | 7.42 ± 1.61 | — | — |
| ITF2374 Cycle 1 Day 1 | 7.42 ± 1.61 | — | — |
| ITF2375 Cycle 1 Day 1 | 8.00 ± 0.0505 | — | — |
| Givinostat Cycle 2 Day 28 | 8.00 ± 0.0340 | 7.98 ± 0.0753 | 7.99 ± 0.0212 |
| ITF2374 Cycle 2 Day 28 | 8.00 ± 0.0340 | 7.98 ± 0.0753 | 7.99 ± 0.0212 |
| ITF2375 Cycle 2 Day 28 | 7.75 ± 1.00 | 8.00 ± 0.00 | — |
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.
| ng*h/mL | Givinostat 100 mg b.i.d. (Part B PK Analysis Set) | Givinostat 75 mg b.i.d. (Part B PK Analysis Set) | Givinostat 50 mg b.i.d. (Part B PK Analysis Set) |
|---|---|---|---|
| Givinostat Cycle 1 Day 1 | 289 ± 130 | — | — |
| ITF2374 Cycle 1 Day 1 | 28.5 ± 14.0 | — | — |
| ITF2375 Cycle 1 Day 1 | 888 ± 439 | — | — |
| Givinostat Cycle 2 Day 28 | 459 ± 145 | 323 ± 107 | 269 ± 78.5 |
| ITF2374 Cycle 2 Day 28 | 216 ± 127 | 161 ± 83.5 | 145 ± 20.9 |
| ITF2375 Cycle 2 Day 28 | 1830 ± 1660 | 1210 ± 585 | — |
PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2374 (Cycle 1 Day 28) across all dose groups and for ITF2375 in the 50 mg b.i.d. dose group was not available for PK analysis.
| ng*h/mL | Givinostat 100 mg b.i.d. (Part B PK Analysis Set) | Givinostat 75 mg b.i.d. (Part B PK Analysis Set) | Givinostat 50 mg b.i.d. (Part B PK Analysis Set) |
|---|---|---|---|
| Givinostat Cycle 1 Day 1 | 372 ± 137 | — | — |
| ITF2375 Cycle 1 Day 1 | 1080 ± 619 | — | — |
| Givinostat Cycle 2 Day 28 | 561 ± 176 | 410 ± 129 | 326 ± 54.0 |
| ITF2375 Cycle 2 Day 28 | 2460 ± 2450 | 1460 ± 608 | — |
Collected over 168 days for Part A and 168 days for Part B (Cycle 1 through Cycle 6 for each phase of study; each cycle 28 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Givinostat DL0 (50 mg b.i.d.) (Part A) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Givinostat DL1 (100 mg b.i.d.) (Part A) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Givinostat DL6 (100 mg + 50 mg) (Part A) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Givinostat at MTD (100 mg b.i.d.) (Part B) | 0/35 (0%) | 2/35 (5.7%) | 35/35 (100%) |
| Event | Givinostat DL0 (50 mg b.i.d.) (Part A) | Givinostat DL1 (100 mg b.i.d.) (Part A) | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Givinostat DL6 (100 mg + 50 mg) (Part A) | Givinostat at MTD (100 mg b.i.d.) (Part B) |
|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/35 |
| ThrombophlebitisVascular disorders | 0/3 | 1/3 | 0/3 | 0/3 | 0/35 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/35 |
| PneumoniaInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 1/35 |
| Event | Givinostat DL0 (50 mg b.i.d.) (Part A) | Givinostat DL1 (100 mg b.i.d.) (Part A) | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Givinostat DL6 (100 mg + 50 mg) (Part A) | Givinostat at MTD (100 mg b.i.d.) (Part B) |
|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 2/3 | 2/3 | 0/3 | 16/35 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 2/3 | 2/3 | 2/3 | 20/35 |
| DyspepsiaGastrointestinal disorders | 1/3 | 2/3 | 0/3 | 0/3 | 5/35 |
| DysgeusiaNervous system disorders | 0/3 | 1/3 | 1/3 | 2/3 | 3/35 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/3 | 0/3 | 0/3 | 0/3 | 1/35 |
| Blood creatinine increasedInvestigations | 0/3 | 0/3 | 0/3 | 1/3 | 14/35 |
| Haemolytic anaemiaBlood and lymphatic system disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/35 |
| PalpitationsCardiac disorders | 0/3 | 1/3 | 0/3 | 0/3 | 3/35 |
| HypothyroidismEndocrine disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/35 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/3 | 8/35 |
The overall baseline population consists of all enrolled patients in either Part A or Part B of the study.
| Age, Categorical(Participants) | Givinostat DL0 (50 mg b.i.d.) (Part A) | Givinostat DL1 (100 mg b.i.d.) (Part A) | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Givinostat DL6 (100 mg + 50 mg) (Part A) | Givinostat at MTD (100 mg b.i.d.) (Part B) | Total Title |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 2 | 1 | 2 | 28 | 35 |
| >=65 years | 1 | 1 | 2 | 1 | 8 | 13 |
| Sex: Female, Male(Participants) | Givinostat DL0 (50 mg b.i.d.) (Part A) | Givinostat DL1 (100 mg b.i.d.) (Part A) | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Givinostat DL6 (100 mg + 50 mg) (Part A) | Givinostat at MTD (100 mg b.i.d.) (Part B) | Total Title |
|---|---|---|---|---|---|---|
| Female | 2 | 1 | 1 | 1 | 11 | 16 |
| Male | 1 | 2 | 2 | 2 | 25 | 32 |
| Race (NIH/OMB)(Participants) | Givinostat DL0 (50 mg b.i.d.) (Part A) | Givinostat DL1 (100 mg b.i.d.) (Part A) | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Givinostat DL6 (100 mg + 50 mg) (Part A) | Givinostat at MTD (100 mg b.i.d.) (Part B) | Total Title |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 3 | 3 | 3 | 36 | 48 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Oct 2013, a primary completion of Jun 2017 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2019, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Givinostat